drugset / Trial / NCT02329301

Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

NCT02329301

RandomizedParallel-groupOpen-labelTreatment

Summary

To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD malaria case incidence and cohort infection incidence in areas of high and low malaria transmission and in a program-relevant manner that will permit adoption and adaptation for wider-scale deployment.

Timeline

Start
2014-09
Primary completion
2016-06
Completion
2020-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule
Subject piperaquine Small molecule